Current Status and Challenges of Precision Medicine in Biliary Tract Cancer

• Published in: Tando Vol. 38; no. 1; pp. 70 - 75
• Main Authors: Kobayashi, Satoshi, Ueno, Makoto
• Format: Journal Article
• Language: Japanese
• Published: Japan Biliary Association 31.03.2024; 一般社団法人 日本胆道学会
• Subjects: biliary tract cancer; cancer genomes; FGFR2 fusion gene; FGFR2融合遺伝子; HER2 gene alteration; HER2遺伝子異常; Precision medicine; がんゲノム; 胆道癌
• ISSN: 0914-0077; 1883-6879
• DOI: 10.11210/tando.38.70

Precision medicine in biliary tract cancer is advancing rapidly with recent advances incomprehensive genomic panel (CGP). In the severe prognosis of biliary tract cancer, precision medicine is an important therapeutic strategy in addition to conventional cytotoxic anticancer drugs and immune checkpoint inhibitors. In particular, the types and rates of cancer gene aberrations vary by subpopulation, such as intrahepatic cholangiocarcinoma and gallbladder cancer, and there are many target molecules such as FGFR2 fusion gene and HER2 gene amplification that can lead to treatment. It is important to link the CGP to precision medicine in biliary tract cancer, including what to use and when to perform the test.